SPOTLIGHT: Schering-Plough touts potential of new drug
Schering-Plough is bullish about its experimental anti-clotting drug, saying it could be a potentially transformational product that can significantly reduce the risk of heart attack and stroke without raising the risk of bleeding. The drug prevents thrombin, a clot-causing protein, from attaching to platelets. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
